BiotechTube
CoaguSense

CoaguSense

Milpitas, United States· Est.
coag-sense.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10.5M

Overview

CoaguSense, founded in 2008, commercializes a point-of-care and home-use PT/INR monitoring system based on direct mechanical clot detection, a methodology considered the clinical gold standard. The company's portable device offers connectivity to EHRs and data management systems, targeting the large market of patients requiring anticoagulation management, particularly for conditions like atrial fibrillation. As a private company, it operates in the competitive in-vitro diagnostics (IVD) sector with a focused product line and a clear value proposition of accuracy and portability.

Cardiovascular

Technology Platform

Direct mechanical clot detection for PT/INR testing, miniaturizing the gold-standard WHO tilt-tube method into a portable, connected device.

Funding History

2
Total raised:$10.5M
Series A$8M
Seed$2.5M

Opportunities

Growth in point-of-care and remote patient monitoring, driven by value-based care, creates demand for accurate, connected devices like Coag-Sense.
The large, established patient population on warfarin therapy provides a substantial addressable market.
Technological differentiation based on gold-standard methodology can be leveraged to gain share in niche segments where accuracy is critical.

Risk Factors

Intense competition from large, entrenched diagnostics companies with greater resources poses a significant commercial challenge.
The market for PT/INR testing faces a long-term threat from the adoption of direct oral anticoagulants (DOACs) that do not require routine monitoring.
Reimbursement complexities for both professional and home testing can impact adoption and profitability.

Competitive Landscape

CoaguSense competes in the point-of-care PT/INR testing market against major players like Roche (CoaguChek series), Abbott (i-STAT, Piccolo), and Siemens Healthineers. It differentiates itself by claiming superior accuracy through direct mechanical clot detection, positioning against competitors that often use optical or electrochemical methods. The competitive landscape is characterized by strong brand loyalty, extensive distribution networks of the incumbents, and ongoing innovation in connectivity and ease-of-use.

More companies in Diagnostics & Precision Medicine →More companies in United States →